Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia

被引：67

作者：

Harris, E

Behrens, J

Samson, D

Rahemtulla, A

Russell, NH

Byrne, JL

机构：

[1] City Hosp Nottingham, Dept Haematol, Nottingham NG5 1PB, England

[2] St Helier Hosp, Dept Haematol, St Helier, Jersey, England

[3] Hammersmith Hosp, Dept Haematol, London, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2003年 / 122卷 / 01期

关键词：

myeloma; renal failure; thalidomide; hyperkalaemia;

D O I：

10.1046/j.1365-2141.2003.04395_2.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：160 / 161

页数：2

共 6 条

[1] Thalidomide for resistant and relapsing myeloma [J].

Alexanian, R ;

Weber, D .

SEMINARS IN HEMATOLOGY, 2000, 37 (01) :22-25

[2] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].

Barlogie, B ;

Desikan, R ;

Eddlemon, P ;

Spencer, T ;

Zeldis, J ;

Munshi, N ;

Badros, A ;

Zangari, M ;

Anaissie, E ;

Epstein, J ;

Shaughnessy, J ;

Ayers, D ;

Spoon, D ;

Tricot, G .

BLOOD, 2001, 98 (02) :492-494

[3]

Cany L, 2002, J CLIN ONCOL, V20, P2212

[4] Thalidomide in multiple myeloma: Current status and future prospects [J].

Cavenagh, JD ;

Oakervee, H .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (01) :18-26

[5]

Sidra G. M., 2002, British Journal of Haematology, V117, P64

[6] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

← 1 →